Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study
- PMID: 17308858
- DOI: 10.1007/s10067-007-0562-9
Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study
Abstract
The aim of the study was to investigate the characteristics of adult clinically amyopathic dermatomyositis (CADM) with rapid progressive interstitial lung disease (ILD). Hospitalized patients with dermatomyositis (DM) and polymyositis (PM) between 1998 and 2005 in the Shanghai Renji Hospital were retrospectively studied. One hundred and forty-five patients were classified into CADM, classic DM or PM according to the modified Sontheimer's definition or Bohan-Peter's classification criteria. They were further stratified based on the presence or absence of clinical ILD. The Kaplan-Meier survival analysis and COX regression were performed. The predictive factors for ILD and other clinical properties of CADM-ILD were explored. The presence of clinical ILD was a significant risk factor for the poor outcome of DM/PM (OR = 4.237, CI 95%: 1.239-14.49, p = 0.021). Other risk factors are the presence of rashes and elevated urea nitrogen. Patients with DM/PM complicated by ILD had different clinical courses. Patients with CADM-ILD showed a rapidly progressive pattern with 6-month survival rate of 40.8%. The DM-ILD manifested a progressive pattern with a 5-year survival rate of 54%, while PM-ILD was chronic with 5- and 10-year survival rate of 72.4% and 60.3%, respectively. Better preserved muscle strength, elevated erythrocyte sedimentation rate, and hypoalbuminemia may herald ILD in DM/PM. Patients with CADM-ILD who later died had lower PO(2), higher lactate dehydrogenase, and prominent arthritis/arthralgia compared with those who survived. The presence of antinuclear antibody seems to be protective. Rapid progressive CADM-ILD is refractory to conventional treatment. ILD is a common complication in over 40% of our hospitalized DM/PM cohort and is also a prominent prognostic indicator. CADM is a special phenotype of DM/PM. CADM-ILD, which is usually rapidly progressive and fatal, requires further investigation.
Similar articles
-
Management of Myositis-Associated Interstitial Lung Disease.Medicina (Kaunas). 2021 Apr 3;57(4):347. doi: 10.3390/medicina57040347. Medicina (Kaunas). 2021. PMID: 33916864 Free PMC article. Review.
-
Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.Springerplus. 2015 May 28;4:240. doi: 10.1186/s40064-015-1013-8. eCollection 2015. Springerplus. 2015. PMID: 26101728 Free PMC article.
-
Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.Respir Investig. 2017 Mar;55(2):130-137. doi: 10.1016/j.resinv.2016.09.006. Epub 2017 Feb 8. Respir Investig. 2017. PMID: 28274528
-
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.J Rheumatol. 2019 Aug;46(8):935-942. doi: 10.3899/jrheum.180825. Epub 2019 May 15. J Rheumatol. 2019. PMID: 31092718
-
The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.Lupus. 2015 Jan;24(1):3-9. doi: 10.1177/0961203314554849. Epub 2014 Oct 8. Lupus. 2015. PMID: 25297551 Review.
Cited by
-
Management of Myositis-Associated Interstitial Lung Disease.Medicina (Kaunas). 2021 Apr 3;57(4):347. doi: 10.3390/medicina57040347. Medicina (Kaunas). 2021. PMID: 33916864 Free PMC article. Review.
-
DNaseI protects against Paraquat-induced acute lung injury and pulmonary fibrosis mediated by mitochondrial DNA.Biomed Res Int. 2015;2015:386952. doi: 10.1155/2015/386952. Epub 2015 Feb 11. Biomed Res Int. 2015. PMID: 25759818 Free PMC article.
-
Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.Front Immunol. 2023 Aug 24;14:1209282. doi: 10.3389/fimmu.2023.1209282. eCollection 2023. Front Immunol. 2023. PMID: 37691917 Free PMC article.
-
Anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis with liver dysfunction: a warning sign of higher death risk.Clin Rheumatol. 2024 Nov;43(11):3389-3397. doi: 10.1007/s10067-024-07093-1. Epub 2024 Sep 17. Clin Rheumatol. 2024. PMID: 39287702
-
Pneumomediastinum in MDA5-associated clinically amyopathic dermatomyositis.Rheumatol Adv Pract. 2017 Aug 31;1(1):rkx003. doi: 10.1093/rap/rkx003. eCollection 2017. Rheumatol Adv Pract. 2017. PMID: 31431943 Free PMC article. No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical